The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -153,678,275 | -579,725 |
| Income from trust | - | 97,051 |
| Stock-based compensation | 140,403,000 | - |
| Prepaid expenses | -4,018 | 14,018 |
| Accrued interest expense - others | - | 19,638 |
| Other assets | -9,851,000 | - |
| Accrued interest expense -related party | - | 35,682 |
| Accounts payable | 521,000 | - |
| Accounts payable and accrued expenses | - | 451,962 |
| Accrued expenses | 1,231,000 | - |
| Net cash used in operating activities | -2,078,488 | -183,512 |
| Cash withdrawn from trust account in connection with redemption | - | 8,617,553 |
| Net cash generated by investing activities | - | 8,617,553 |
| Business combination | 26,000 | - |
| Proceeds from related party loans | 9,744,230 | 166,770 |
| Redemption of ordinary shares | - | 8,617,553 |
| Payments of deferred offering costs | 7,602,000 | - |
| Net cash (used in) provided by financing activities | 10,785,783 | -8,450,783 |
| Net change in cash and cash equivalents | 89,742 | -16,742 |
| Cash and cash equivalents at beginning of period | 12,000 | - |
| Cash and cash equivalents at end of period | 85,000 | - |
Semnur Pharmaceuticals, Inc. (DNQAF)
Semnur Pharmaceuticals, Inc. (DNQAF)